 EMERYVILLE, Calif., April 16, 2021 GLOBE NEWSWIRE -- Zogenix NASDAQ: ZGNX, a global biopharmaceutical company developing rare disease therapies, today announced new findings from an investigator-initiated study designed to assess caregivers perspectives on the long-term seizure- and non-seizure-related benefits of FINTEPLA fenfluramine on patients with Dravet syndrome, a rare, severe epilepsy, and on their caregivers and families. Data from the study is being presented during the virtual American Academy of Neurology AAN Annual Meeting, April 17-22, 2021. 